Topics:
Thoracic Malignancies • Medical Oncology
What is your preferred second line therapy for patients with metastatic large cell neuroendocrine carcinoma of the lung after progression on first line chemo-immunotherapy?
Is your decision swayed by RB1 status or by duration since platinum therapy?
Answer from: Medical Oncologist at Community Practice
Let's start by backtracking to the original treatment recommendation. Since large cell neuroendocrine carcinomas (LCNEC) of the lung can harbor mutations in EGFR or BRAF or even ALK rearrangements, next generation sequencing is appropriate for patients with advanced disease.Assuming no targetable al...
Sign in or Register to read more